Pricing Log in Create free account
Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bio-Techne Corp (TECH) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Bio-Techne Corp (TECH) trades at a EV/Sales of 9.3×. Over the past ten years it has ranged from 5.6× (May 2026) to 22.5× (September 2021); the current reading is higher than 44% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2026 9.0× 32.62%
FY2025 6.8× (31.24%)
FY2024 9.9× (13.38%)
FY2023 11.4× (7.13%)
FY2022 12.3× (34.75%)
FY2021 18.9× 36.91%
FY2020 13.8× 19.26%
FY2019 11.5× 29.99%
FY2018 8.9× 9.43%
FY2017 8.1× (3.29%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 9.0× 33.72%
Mar 2026 6.7× (11.44%)
Dec 2025 7.6× 5.19%
Sep 2025 7.2× 6.46%
42 more quarters

Against its own ten years

Low 5.6× High 22.5×
Ten-year median 9.8×
Current reading's percentile 39

EV/Sales against peers

Company EV/Sales
PCVX Vaxcyte, Inc. compare n/m
BMRN BioMarin Pharmaceutical Inc. compare 4.1×
TECH Bio-Techne Corp 9.3×
MDGL Madrigal Pharmaceuticals, Inc. compare 9.8×
CORT Corcept Therapeutics Incorporated compare 13.6×
KRYS Krystal Biotech, Inc. compare 19.3×
BBIO BridgeBio Pharma, Inc. compare 19.9×
IBRX ImmunityBio, Inc. compare 63.6×
SMMT Summit Therapeutics PLC compare 15,310×
Biotechnology industry median 9.2×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on TECH